marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Aptevo Therapeutics Balance Sheet 2011-2025 | APVO
Annual Balance Sheet Aptevo Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-20.8 M | -40.3 M | -35 M | 10.7 M | -11.4 M | 12 M | 8.71 M | -4.64 M | -3.59 M | - | - | - | |
Long Term Debt |
- | 1.46 M | 3.71 M | 5 M | - | 19.3 M | 15.7 M | 18.4 M | - | - | - | - | - |
Long Term Debt Current |
700 K | 400 K | 1 M | 5 M | 19.9 M | - | 3.33 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 5 M | 3.33 M | 19.5 M | 16.5 M | 21.7 M | 3.9 M | 5.53 M | - | - | - |
Total Current Liabilities |
7.22 M | 8.71 M | 34.8 M | 14.5 M | 38.2 M | 17.6 M | 18.5 M | 19.5 M | - | - | - | - | - |
Total Liabilities |
12.6 M | 16.2 M | 55.4 M | 37 M | 41.6 M | 37.1 M | 35 M | 41.3 M | 23.8 M | 25.4 M | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 811 K | 3.84 M | 880 K | - | - | - |
Retained Earnings |
-223 M | -206 M | -214 M | - | -168 M | -127 M | -73.7 M | -80.7 M | -232 M | -173 M | - | - | - |
Total Assets |
24.8 M | 34.2 M | 56.6 M | 53.5 M | 53.4 M | 67.5 M | 117 M | 91.9 M | 112 M | 120 M | - | - | - |
Cash and Cash Equivalents |
16.9 M | 22.6 M | 45 M | 40 M | 12.4 M | 30.6 M | 7.1 M | 9.68 M | 4.64 M | - | - | - | - |
Book Value |
12.2 M | 18 M | 1.22 M | 16.6 M | 11.8 M | 30.4 M | 82 M | 50.6 M | 88.6 M | 94.6 M | - | - | - |
Total Shareholders Equity |
12.2 M | 18 M | 1.22 M | 16.6 M | 11.8 M | 30.4 M | 82 M | 50.6 M | 88.6 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aptevo Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
4.83 M | 5.02 M | 5.21 M | 5.4 M | 5.6 M | 5.7 M | 5.9 M | 1.46 M | 6.2 M | 6.4 M | 1.1 M | 3.71 M | 1.61 M | 1.87 M | 2.12 M | 28.2 M | 2.36 M | 2.36 M | 2.36 M | 3.33 M | 3.33 M | 19.6 M | 19.4 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
10.7 M | 10.5 M | 11.5 M | 12.6 M | 12.4 M | 12.7 M | 11.7 M | 16.2 M | 15.9 M | 15.8 M | 51.1 M | 55.4 M | 56.7 M | 57.6 M | 58.2 M | 37 M | 37 M | 37 M | 37 M | 41.6 M | 41.6 M | 41.6 M | 41.6 M | 37.1 M | 37.1 M | 37.1 M | 37.1 M | 35 M | 35 M | 35 M | 35 M | 41.3 M | 41.3 M | 41.3 M | 41.3 M | 39.1 M | 23.8 M | 23.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.44 M | 878 K | 811 K | 811 K | 811 K | 811 K | 3.84 M | 3.84 M | 3.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-241 M | -236 M | -230 M | -223 M | -218 M | -211 M | -203 M | -206 M | -201 M | -194 M | -222 M | -214 M | -208 M | -201 M | -193 M | -186 M | -186 M | -186 M | -186 M | -168 M | -168 M | -168 M | -168 M | -127 M | -127 M | -127 M | -127 M | -73.7 M | -73.7 M | -73.7 M | -73.7 M | -80.7 M | -80.7 M | -80.7 M | -80.7 M | -232 M | -232 M | -232 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
15.1 M | 14.9 M | 17.6 M | 24.8 M | 27.1 M | 28.9 M | 35 M | 34.2 M | 31.7 M | 38.8 M | 45.2 M | 56.6 M | 64 M | 71.5 M | 68.8 M | 53.5 M | 53.5 M | 53.5 M | 53.5 M | 53.4 M | 53.4 M | 53.4 M | 53.4 M | 67.5 M | 67.5 M | 67.5 M | 67.5 M | 117 M | 117 M | 117 M | 117 M | 91.9 M | 91.9 M | 91.9 M | 91.9 M | 128 M | 112 M | 112 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
7.75 M | 8.07 M | 10.2 M | 16.9 M | 19.1 M | 21 M | 25.3 M | 22.6 M | 22.2 M | 29.4 M | 35 M | 45 M | 52.1 M | 60.4 M | 57.5 M | 40 M | 40 M | 40 M | 40 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 7.1 M | 7.1 M | 7.1 M | 7.1 M | 9.68 M | 9.68 M | 9.68 M | 9.68 M | 4.64 M | 4.64 M | 4.64 M | - | 3.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
4.42 M | 4.46 M | 6.1 M | 12.2 M | 14.7 M | 16.3 M | 23.3 M | 18 M | 15.8 M | 23 M | -5.88 M | 1.22 M | 7.29 M | 13.9 M | 10.5 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 82 M | 82 M | 82 M | 82 M | 50.6 M | 50.6 M | 50.6 M | 50.6 M | 88.6 M | 88.6 M | 88.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
4.42 M | 4.46 M | 6.1 M | 12.2 M | 14.7 M | 16.3 M | 23.3 M | 18 M | 15.8 M | 23 M | -5.88 M | 1.22 M | 7.29 M | 13.9 M | 10.5 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 30.4 M | 30.4 M | 30.4 M | 30.4 M | 82 M | 82 M | 82 M | 82 M | 50.6 M | 50.6 M | 50.6 M | 50.6 M | 88.6 M | 88.6 M | 88.6 M | - | 94.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency